UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 651

Sortiert nach

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

The lancet oncology, 2018-06, Vol.19 (6), p.737-746

2018

Volltextzugriff (PDF)

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

The Lancet (British edition), 2017-03, Vol.389 (10075), p.1195-1205

2017

Volltextzugriff (PDF)

Challenges of Guarantee-Time Bias

Journal of clinical oncology, 2013-08, Vol.31 (23), p.2963-2969

2013

Volltextzugriff (PDF)

Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

JNCI : Journal of the National Cancer Institute, 2019-08, Vol.111 (8), p.772-781

2019

Volltextzugriff (PDF)

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

Journal of clinical oncology, 2016-03, Vol.34 (9), p.927-935

2016

Volltextzugriff (PDF)

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

The New England journal of medicine, 2017-07, Vol.377 (2), p.122-131

2017

Volltextzugriff (PDF)

Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis

BMJ (Online), 2021-12, Vol.375, p.e066381

2021

Volltextzugriff (PDF)

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Journal of clinical oncology, 2016-04, Vol.34 (10), p.1034-1042

2016

Volltextzugriff (PDF)

Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node–Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX

Journal of clinical oncology, 2013-09, Vol.31 (25), p.3083-3090

2013

Volltextzugriff (PDF)

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

The lancet oncology, 2014-09, Vol.15 (10), p.1137-1146

2014

Volltextzugriff (PDF)

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial

The lancet oncology, 2014-02, Vol.15 (2), p.156-163

2014

Volltextzugriff (PDF)

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

The New England journal of medicine, 2015-03, Vol.372 (10), p.923-932

2015

Volltextzugriff (PDF)

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Journal of clinical oncology, 2021-05, Vol.39 (13), p.1448-1457

2021

Volltextzugriff (PDF)

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

Journal of clinical oncology, 2020-04, Vol.38 (12), p.1293-1303

2020

Volltextzugriff (PDF)

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

Journal of clinical oncology, 2014-07, Vol.32 (20), p.2159-2165

2014

Volltextzugriff (PDF)

Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Clinical cancer research, 2021-08, Vol.27 (15), p.4311-4324

2021

Volltextzugriff (PDF)

Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables

Journal of clinical oncology, 2008-08, Vol.26 (24), p.3913-3915

2008

Volltextzugriff (PDF)

Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From a Herceptin Adjuvant Trial

Journal of clinical oncology, 2013-07, Vol.31 (21), p.2692-2698

2013

Volltextzugriff (PDF)

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

The lancet oncology, 2011-11, Vol.12 (12), p.1101-1108

2011

Volltextzugriff (PDF)

Sex and cancer immunotherapy: Current understanding and challenges

Cancer cell, 2022-07, Vol.40 (7), p.695-700

2022

Volltextzugriff (PDF)

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study

Journal of clinical oncology, 2017-04, Vol.35 (11), p.1179-1188

2017

Volltextzugriff (PDF)

1 – 25 von 651

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(637)
Mit Volltextzugriff
(485)

Publikationsform

Sprache

Englisch
(650)
Japanisch
(63)
Russisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(460)
Science & Technology
(388)
Female
(381)
Life Sciences & Biomedicine
(381)
Oncology
(271)
Breast Cancer
(232)
Breast Neoplasms - Drug Therapy
(225)
Medical Sciences
(159)
Biological And Medical Sciences
(158)
Middle Aged
(132)
Chemotherapy, Adjuvant
(129)
Breast Neoplasms - Pathology
(127)
Adult
(114)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(113)
Chemotherapy
(112)
Tumors
(100)
Breast Neoplasms - Surgery
(93)
Aged
(91)
Treatment Outcome
(88)
Disease-Free Survival
(86)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Challenges of Guarantee-Time Bias

Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node–Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials

Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables

Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From a Herceptin Adjuvant Trial

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

Sex and cancer immunotherapy: Current understanding and challenges

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study

Suchergebnisse filtern